ClinicalTrials.gg
RecruitingNCT04949451TRIMMUpdated Aug 26, 2025

Time Restricted Feeding, Muscle, and Metabolism

An interventional study of Whey protein supplement and Ketogenic aid in Overweight and Obesity, sponsored by University of Arkansas, Fayetteville. Recruiting at 1 site in United States. Open to participants aged 25 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-08-26.

Primary conditionObesityRegistry: OverweightReclassifiedWhy we changed it
Registry
Overweight — the first condition term the registry derived for this study.
ClinicalTrials.gg
Obesity
Why
  1. The study's listed conditions name Obesity, a narrower term within Overweight.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by University of Arkansas, Fayetteville · Not applicable, Interventional, and Basic science

How we know

From the registry’s dates

  • Started Jun 2021; still recruiting 5 years 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
90
Allocation
Randomized
Ages
25 Years to 50 Years
Sex
All
01

Study summary

Effective nutrition strategies for combatting and/or preventing obesity still need to be identified. This has been the case despite the numerous and different approaches that have been taken. Potential targets for combatting/preventing obesity have been identified, but long-term solutions have not emerged. This study uses time restricted feeding to study the role of dietary protein in obesity prevention and/or treatment. The objectives are to determine the role of skeletal muscle mass as a driver of energy-sensing mechanisms and peripheral signals that regulate appetite and energy intake in overweight and obese adults and to determine the effects of protein timing on muscle mass to regulate appetite and energy intake in overweight and obese adults.

02

Conditions studied

  • Overweight
  • Obesity

Browse trials for

03

In context

Obesity Reclassified

11,564 studies on the registry are indexed under Obesity; 2,063 are open to participants now.

This study's planned enrollment of 90 is above the median of 67 across 9,043 interventional studies indexed under Obesity.

Browse Obesity studies →

Lead sponsor

University of Arkansas, Fayetteville is the lead sponsor of 29 studies on the registry; 7 are open to participants now.

Compared within Obesity, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Overweight. The counts are of registry records indexed under each term, refreshed daily. How we classify →

04

Who can participate

Ages eligible
25 Years to 50 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Resides in Northwest Arkansas
  • Age 25-50 years
  • > 25
  • All ethnicities
  • Female and male

Exclusion criteria

Exclusion Criteria:

  • Food allergies
  • Pregnant or breastfeeding
  • Dietary restrictions (e.g. vegetarian, vegan, etc.)
  • Trying to lose weight in last 3 months
  • Pre-existing health conditions related to obesity (e.g. cardiovascular disease, diabetes, hypertension)
  • Prescription medications related to heart disease or type 2 diabetes
  • Fear of needles
  • Smoker or vaping
  • Currently taking protein supplements or other nutritional supplements which may interfere with study outcomes
  • Consumes >4 alcoholic beverages per week
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
90 participants (estimated)

Study arms

  • Placebo comparator
    TRF-C

    Follows time restricted feeding protocol.

    Other: Control group - time restricted feeding only

  • Experimental
    TRF-P

    Follows time restricted feeding protocol, consumes protein supplement

    Dietary Supplement: Whey protein supplement

  • Experimental
    TRF-S

    Follows time restricted feeding protocol, consumes ketogenic supplement

    Dietary Supplement: Ketogenic aid

Interventions

  • Dietary supplementWhey protein supplement

    Participants consume whey protein at the beginning of the eating period.

  • Dietary supplementKetogenic aid

    Participants consume ketogenic aid upon waking.

  • OtherControl group - time restricted feeding only

    Time restricted feeding.

06

What researchers measure

Primary outcomes

  1. Body composition

    Body composition measured using dual x-ray absorptiometry to determine the ration of lean/fat-free mass to fat mass.

    Time frame: Change is being assessed at baseline and final day (day 120) of the intervention.

Secondary outcomes

  1. Whole body protein turnover

    Whole body protein turnover will be measured using 15N-alanine

    Time frame: Change is being assessed at baseline and final day (day 120) of the intervention.

  2. Muscle mass

    Muscle mass will be measured using D3-creatine

    Time frame: Change is being assessed at baseline and final day (day 120) of the intervention.

  3. Body weight

    Body weight will be measured in kilograms.

    Time frame: Change is being assessed at baseline, 4, 8, and 12 weeks.

  4. Sleep

    Sleep will be assessed using wrist Actigraphy for sleep duration and total time in bed.

    Time frame: Change is being assessed at baseline and 12 weeks

  5. Sleep Quality

    Sleep quality will be measured using the Pittsburgh Sleep Quality Index survey

    Time frame: Change is being assessed at baseline, 4, 8, and 12 weeks

  6. Mood

    Mood will be assessed using the Profile of Mood States Questionnaire

    Time frame: Change is being assessed at baseline, 4, 8, and 12 weeks

  7. Grit

    Grit will be assessed using the grit questionnaire.

    Time frame: Change is being assessed at baseline, 4, 8, and 12 weeks

  8. Self-reported physical activity

    Physical activity will be measured using the iPAQ survey

    Time frame: Change is being assessed at baseline, 4, 8, and 12 weeks

  9. Dietary intake

    Dietary intake will be measured using weighed, 3-day food records

    Time frame: Change is being assessed at baseline, 4, 8, and 12 weeks

  10. Fasting glucose

    Glucose will be measured as mg/dl

    Time frame: Change is being assessed at baseline, 4, 8, and 12 weeks

  11. Hand grip

    Hand grip will be measured using a dynamometer.

    Time frame: Change is being assessed at baseline, 4, 8, and 12 weeks

  12. Amino acids and metabolites

    Blood will be collected and plasma amino acids and metabolites will be assessed using commercially available kit for amino acid analysis for all circulating amino acids.

    Time frame: Change is being assessed at baseline, 4, 8, and 12 weeks

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2021 to primary completion in Apr 2025, 46 months.

Of 3,697 non-industry interventional studies with no phase under Obesity, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 43. This study's 46 months is above that.

Counting every sponsor, half of 3,861 studies reached it within 22 months; a quarter within 9 and three quarters within 42.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 16, 2021
First posted
Jul 2, 2021
StartActual
Jun 13, 2021
Primary completionActual
Apr 30, 2025
CompletionEst.
Dec 30, 2025
Last update
Aug 26, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 26, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04949451
Lead sponsor
University of Arkansas, Fayetteville
Responsible party
Jamie Baum (Associate Professor, University of Arkansas, Fayetteville) — Principal investigator
First posted
Jul 2, 2021
Start date
Jun 13, 2021
Primary completion
Apr 30, 2025
Completion
Dec 30, 2025 (estimated)
Last update
Aug 26, 2025

Study contacts

Jamie Baum, PhD
Contact
baum@uark.edu
479-575-4474

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion